


# CHAIRMEN



**Dr Robert Marcus**  
*King's College Hospital*

Dr Robert Marcus, MA, FRCP, FRCPath is Consultant Haematologist at King's College Hospital, London. He qualified in Medicine from University College Hospital Medical School in London in 1977 and specialised in haematology at the Royal Postgraduate Medical School and the Royal Free Hospital. Prior to joining King's in 2008, Dr Marcus was Consultant Haematologist in Addenbrooke's Hospital in Cambridge for 20 years where he established the bone marrow transplant unit and developed a particular interest in lymphoma and related disorders.

Dr Marcus' research interests include the development of novel therapies for lymphoma, and has been a Chief Investigator in a large number of practice changing studies. Recently he has developed further expertise in the management of cerebral lymphoma and lymphoproliferative disorders in patients with HIV and after organ transplantation. Dr Marcus was until recently the chairman of the NCRI low-grade lymphoma working party designing new studies in this field and has been examiner for the Royal College of Pathologists.

He is medical advisor to the Lymphoma Association, and Vice President of Leukaemia Care. Dr Marcus has authored more than 150 peer-reviewed manuscripts and reviews, including national guidelines on follicular, cerebral and post transplant lymphoma. He has co-edited 4 books, including new text books on multiple myeloma and lymphoma, published in 2013 by Cambridge University Press. Special interests: haemato-oncology, with a special interest in lymphoma, Hodgkins disease and other lymphoproliferative disorders of blood and bone marrow.



**Professor David Linch**  
*University College London*

David Linch, FRCP, FRCPath, FMedSci is Professor of Haematology and Head of the Department of Haematology at University College London (UCL). He qualified in Medicine from Cambridge University and the Middlesex Hospital Medical School in 1975, and then undertook SHO and Registrar positions in General Medicine before entering Haematology.

He commenced his research career at UCL as a Wellcome Trust Clinical Research Fellow and then an MRC Travelling Research Fellow to the Dana Faber Cancer Institute in Boston. In 1984 he was appointed to a Senior Lectureship at the Middlesex Hospital and following the first of several London Medical School mergers he was appointed to a Chair of Haematology at UCL in 1988. He took up the Headship of the Department of Haematology in 1992 and from 2004 to 2007 was the Chairman of the Division of Cancer Medicine at UCL.

He is currently the Director of the UCL/UCLH Biomedical Research Centre Cancer Programme. His laboratory research has been in the field of myelopoiesis and myeloid leukaemias and his clinical research has been focussed on the treatment of leukaemia and lymphoma with a particular focus on the development of high dose therapy strategies. He was the Goulstonian Lecturer of the Royal College of Physicians in 1988 and the recipient of the British Society of Haematology Gold Medal in 2006. Professor Linch was the Director of the British National Lymphoma Investigation, Chairman of the UK Lymphoma Group and then the first Chairman of the NCRI Lymphoma Clinical Studies Group. He has published numerous papers and has an H-factor of 76. He is the President of the Lymphoma Association, a national patient advisory and support organisation.

# SPEAKERS

## **Dr Cathy Burton** *HMDS Leeds*

Dr Cathy Burton studied medicine at University of Cambridge. After Haematology training in London, she moved to Leeds, completing a MD in Hodgkin lymphoma and then became an Academic Clinical Lecturer. In 2009, Dr Burton was appointed as a Consultant Haematologist at St James's University Hospital, Leeds, specialising in Lymphoma and Diagnostics. In 2014 she became Clinical Lead of the Haematological Malignancy Diagnostic Service in Leeds. She is a member of the NCRI Lymphoma Clinical Studies Group and Hodgkin lymphoma subgroup as well as a member of the Lunenburg Lymphoma Biomarker Consortium, an international collaboration studying the application of biomarker analyses to clinical practice in lymphoma.



## **Dr Stephen Robinson** *University Hospital Bristol*

Dr Robinson trained in medicine at the Royal Free Hospital, London graduating in 1992. He trained in Haematology between 1995 and 2002 at University College London. He was awarded a PhD for research into developmental aspects of human dendritic cells in 1998. Since 2002 he has worked as a Consultant Haematologist in the Bone Marrow Transplant Unit at University Hospital Bristol with a specialist interest in malignant lymphoma and stem cell transplantation. Since 2014 he has been the Clinical Director of the Bristol Cancer Institute. Dr Robinson is currently conducting research into reduced intensity allogeneic stem cell transplantation in lymphoma and is the Scientific Secretary of the EBMT Lymphoma Working Party.



## **Dr George Follows** *Addenbrooke's Hospital*

Dr Follows received his Medical degree from Oxford University Medical School before completing his medical training in Newcastle, Edinburgh and PhD at Leeds University. After a period in post-doctoral research at Cambridge University, he was appointed Clinical Lead for lymphoproliferative disorders and haematology clinical trials in Cambridge in 2007. He chaired the UK CLL Forum from 2012 to 2016 and has authored / co-authored peer reviewed papers published in many of the world's leading medical journals covering various areas of haematological biology and malignancy.



## **Dr Graham Collins** *Oxford University Hospitals*

Dr Collins trained in medicine at Cambridge and St Bartholomew's and the Royal London Hospitals. His specialist haematology training was in Oxford. Dr Collins chairs the Hodgkin lymphoma national study group and T cell lymphoma working group. He was also a member of the lymphoma guidelines development group of NICE and co-authored the national guidelines for relapsed Hodgkin Lymphoma.





**Dr Christopher McNamara**  
**University College London Hospital**

Dr Christopher McNamara is a Consultant Haematologist at University College London Hospital. He was previously consultant haematologist at the The Royal Free London. His interests include clinical trials and lymphoma diagnostics.



**Dr Kate Cwynarski**  
**University College London Hospital**

Dr Kate Cwynarski is a Haem-Oncologist specialising in Lymphoma and CLL at University College London Hospital, London, UK. She trained at King's College, Hammersmith Hospital and Royal Free Hospital, London UK and received her MRC-funded PhD in immunology at Imperial College, London, UK.

Her sub-specialist interests include Primary Central Nervous System (CNS) Lymphoma, HIV-related lymphoma and T-cell Lymphomas. She is Co-lead of the UK Primary CNS Lymphoma (PCNSL) Group and is a member of the National Cancer Research Institute (NCRI) Lymphoma Clinical Studies Group.

Dr. Cwynarski is involved in many clinical trials, has co-authored BCSH guidelines and she has authored or co-authored over 50 journal articles in *Lancet Haematology*, *Journal of Clinical Oncology*, *Blood*, *AIDS*, *British Journal of Haematology* and *Bone Marrow Transplant*.



**Dr Wendy Osborne**  
**Freeman Hospital, Newcastle**

Dr Wendy Osborne is a Consultant Haematologist at the Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust. She graduated with First Class Honours from Newcastle University in 1998 and completed her General Medical Training at Queens Medical Centre, Nottingham. Dr Osborne worked in haematology departments in Glasgow before returning to Newcastle to undertake Higher Specialist Training.

Dr Osborne is a member of the NCRI High Grade lymphoma sub-group and BSH lymphoma special interest group and is a principal investigator and co-investigator for numerous clinical trials. Dr Osborne is the teaching lead for the haematology undergraduate programme at Newcastle University and was appointed Associate Lecturer status in 2016.



**Professor Simon Rule**  
**Derriford Hospital, Plymouth**

Professor Rule is Consultant Haematologist in Derriford Hospital Plymouth and Professor of Clinical Haematology at Plymouth University Medical School. He is Associate Medical Director for R & D director at Derriford and chair of the NCRN low grade lymphoma trials committee. He sits on the clinical trials committee for Leukaemia and Lymphoma Research and on the editorial board of *Haematologica*. His specific area of interest is in mantle cell lymphoma and is currently the chief investigator for multiple studies being conducted at local, national and international level. He is an author on over 140 publications.

## **Dr Christopher Fox**

### **Nottingham University Hospitals**

Christopher Fox is a Consultant Haematologist at Nottingham University Hospitals NHS Trust. He was awarded a PhD from the University of Birmingham for research into Epstein-Barr virus and the pathogenesis of T and NK lymphoproliferative disease and remains involved in this field of research.

He is a member of the NCRI Lymphoma Clinical Studies Group, a core member of the high-grade sub-group, the T cell working group, and co-chairs the CNS lymphoma working group. He is Principal Investigator for multiple phase I-III studies in lymphoma and CLL. He has published papers in peer-reviewed journals including Lancet Haematology, Blood, Leukemia, Clinical Infectious Diseases, Haematologica, British Journal of Haematology and Bone Marrow Transplantation.



## **Dr Andrew McMillan**

### **Nottingham University Hospitals**

Dr Andrew McMillan is a Consultant Haematologist at Nottingham University Hospitals NHS Trust and has a specialist interest in the treatment of lymphoma. He has previously Chaired the National Cancer Research Institute High Grade Lymphoma Subgroup. He has been Chief Investigator or UK lead on a number of NCRI and International clinical research protocols. He is also a member of the NCRI acute lymphoblastic leukaemia subgroup and the National Chemotherapy Clinical Reference group.

He trained at University College Hospital and the Royal Free Hospital and has published papers and on Lymphoma, Acute Lymphoblastic Leukaemia and Autologous Stem cell Transplantation.



## **Professor Karl Peggs**

### **University College London Hospital**

Karl Peggs is a Senior Lecturer in Stem Cell Transplantation and Immunotherapy at UCL and Honorary Consultant in Haematology/Transplantation at UCL Hospitals. He received his preclinical training and MA at Cambridge University, completing his clinical training at Oxford University Medical School. Following qualification he completed general medical training at Addenbrookes Hospital Cambridge, and specialist haematology training at the John Radcliffe Hospital, Oxford and subsequently UCLH, London. During this time he spent three years in the research group of Professor Stephen Mackinnon, establishing adoptive cellular therapies for cytomegalovirus. After taking the position of Senior Lecturer at UCL in 2003, he spent 2 years at Memorial Sloan Kettering Cancer Institute, New York, in the laboratory of Professor James Allison, studying murine models of regulatory checkpoint blockade.

His research interests include immune reconstitution, pathogen-specific adoptive cellular therapies, and regulatory checkpoint-directed immunotherapeutics. He is member of the Leukaemia and Lymphoma Research Clinical Trials Committee, a Trustee of the Teens Unite charity, and has contributed to several international working parties on infectious complications and relapse following stem cell transplantation. He is Chief Investigator for 4 UKCRN national studies investigating transplantation in Hodgkin Lymphoma and cellular therapies for cytomegalovirus.

